UNION therapeutics announces presentation of preliminary data on Phase 2a investigator-initiated study with orismilast at the 12th EHSF Conference and provides study update
· Poster presentation of preliminary data from the Phase 2a investigator-initiated study OSIRIS at the 12th EHSF Conference · Hidradenitis suppurativa (HS) is a scarring, painful, inflammatory skin disease with few or no good treatment options · FDA has granted Fast Track designation to oral orismilast for treatment of moderate to severe HS · Orismilast is a high-potency PDE4 inhibitor with broad anti-inflammatory properties also in development for oral treatment of psoriasis and atopic dermatitis (AD) Hellerup, Denmark, February 7, 2023 – UNION therapeutics A/S (UNION), a